Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8
Humans
Antibodies, Monoclonal, Humanized
/ pharmacology
Female
Adult
Male
Herpesvirus 4, Human
/ immunology
CD8-Positive T-Lymphocytes
/ drug effects
Middle Aged
Immunologic Factors
/ pharmacology
Multiple Sclerosis, Relapsing-Remitting
/ drug therapy
T-Lymphocytes, Cytotoxic
/ drug effects
Prospective Studies
Cell Proliferation
/ drug effects
Killer Cells, Natural
/ drug effects
Lymphocyte Activation
/ drug effects
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
ppublish
Résumé
The role of B cells in the pathogenic events leading to relapsing multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this role has been provided by therapeutic efficacy of anti-CD20 monoclonal antibodies. Indeed, treatment with anti-CD20 can also alter number and function of other immune cells not directly expressing CD20 on their cell surface, whose activities can contribute to unknown aspects influencing therapeutic efficacy. We examined the phenotype and function of cytotoxic lymphocytes and Epstein-Barr virus (EBV)-specific immune responses in people with R-MS before and after ocrelizumab treatment. In this prospective study, we collected blood samples from people with R-MS (n = 41) before and 6 and 12 months after initiating ocrelizumab to assess the immune phenotype and the indirect impact on cytotoxic functions of CD8 We observed that while ocrelizumab depleted circulating B cells, it also reduced the expression of activation and migratory markers on both CD8 Taken together, our findings suggest that ocrelizumab-while depleting B cells-affects the cytotoxic function of CD8
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The role of B cells in the pathogenic events leading to relapsing multiple sclerosis (R-MS) has only been recently elucidated. A pivotal step in defining this role has been provided by therapeutic efficacy of anti-CD20 monoclonal antibodies. Indeed, treatment with anti-CD20 can also alter number and function of other immune cells not directly expressing CD20 on their cell surface, whose activities can contribute to unknown aspects influencing therapeutic efficacy. We examined the phenotype and function of cytotoxic lymphocytes and Epstein-Barr virus (EBV)-specific immune responses in people with R-MS before and after ocrelizumab treatment.
METHODS
METHODS
In this prospective study, we collected blood samples from people with R-MS (n = 41) before and 6 and 12 months after initiating ocrelizumab to assess the immune phenotype and the indirect impact on cytotoxic functions of CD8
RESULTS
RESULTS
We observed that while ocrelizumab depleted circulating B cells, it also reduced the expression of activation and migratory markers on both CD8
DISCUSSION
CONCLUSIONS
Taken together, our findings suggest that ocrelizumab-while depleting B cells-affects the cytotoxic function of CD8
Identifiants
pubmed: 38662990
doi: 10.1212/NXI.0000000000200250
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ocrelizumab
A10SJL62JY
Immunologic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM